From the interpretation of all the available studies in this field, it has become clear that target TCs may differ depending on the administered anti-TNF agent, the measurement time point, the IBD phenotype and severity and, lastly, but foremost, the desired outcome of interest. Here, TNF is linked to inflammatory bowel disease.